These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Comments on ethical issues with implantable defibrillators by F. James Brennan. Rahmoeller G Pacing Clin Electrophysiol; 2004 Jul; 27(7):899. PubMed ID: 15271006 [No Abstract] [Full Text] [Related]
28. Anti-arrhythmic effects of statins: a hypothesis remains to be tested. Guo HM Heart Rhythm; 2008 Apr; 5(4):511-2. PubMed ID: 18362017 [No Abstract] [Full Text] [Related]
29. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial. Kloppe A; Proclemer A; Arenal A; Lunati M; Martìnez Ferrer JB; Hersi A; Gulaj M; Wijffels MC; Santi E; Manotta L; Mangoni L; Gasparini M Circulation; 2014 Jul; 130(4):308-14. PubMed ID: 24838360 [TBL] [Abstract][Full Text] [Related]
30. The role of pharmacotherapy in the prevention of sudden cardiac death in patients with heart failure. Weeks PA; Sieg A; Gass JA; Rajapreyar I Heart Fail Rev; 2016 Jul; 21(4):415-31. PubMed ID: 27003591 [TBL] [Abstract][Full Text] [Related]
31. Clinical trials update: sudden cardiac death prevention by implantable device therapy. Finch NJ; Leman RB Crit Care Nurs Clin North Am; 2005 Mar; 17(1):33-8, x. PubMed ID: 15749399 [TBL] [Abstract][Full Text] [Related]
32. Wearable cardioverter-defibrillator as a bridge to implantable cardioverter-defibrillator treatment. Technol Eval Cent Assess Program Exec Summ; 2010 Nov; 25(2):1-5. PubMed ID: 21638938 [No Abstract] [Full Text] [Related]
33. Does the arrhythmic risk of patients with ischaemic cardiomyopathy really benefit from revascularisation therapy? Kallergis EM; Mavrakis HE; Vardas PE Hellenic J Cardiol; 2008; 49(4):203-6. PubMed ID: 18935706 [No Abstract] [Full Text] [Related]
35. How implantable cardioverter-defibrillators work and simple programming. Bryant RM Cardiol Young; 2017 Jan; 27(S1):S121-S125. PubMed ID: 28084970 [TBL] [Abstract][Full Text] [Related]
36. Prevention of sudden cardiac death: the role of the implantable cardioverter-defibrillator. Sinha SK; Mehta D; Gomes JA Mt Sinai J Med; 2005 Jan; 72(1):1-9. PubMed ID: 15682255 [TBL] [Abstract][Full Text] [Related]
37. [Indications for an implantable cardioverter/defibrillator]. Schwab JO; Lüderitz B Internist (Berl); 2007 Jul; 48(7):715-23; quiz 724-5. PubMed ID: 17541533 [TBL] [Abstract][Full Text] [Related]
38. [Correlation of Tp-e interval and Tp-e/Q-T ratio with malignant ventricular arrhythmia in patients with implantable cardioverter-defibrillator for primary prevention]. Zhu TY; Teng SE; Chen YY; Liu SR; Meng SR; Peng J Nan Fang Yi Ke Da Xue Xue Bao; 2016 Mar; 36(3):401-4. PubMed ID: 27063171 [TBL] [Abstract][Full Text] [Related]
39. [Anxiety and anxiety management in patients with implanted cardioverter-defibrillators]. Ladwig KH; Wirsching C; V Hammerstein A; Danner R; Baumert J; Schmitt C Dtsch Med Wochenschr; 2004 Oct; 129(43):2311-5. PubMed ID: 15483771 [No Abstract] [Full Text] [Related]
40. The marriage of true minds: the partner of the ICD patient as a new focus for study. Newman D; Crystal E Pacing Clin Electrophysiol; 2010 Dec; 33(12):1427-9. PubMed ID: 20946277 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]